Special Issue

Discovery of Small Molecules for Cancer Therapy: Current Challenges, Recent Trends, and Future Perspectives

Message from the Guest Editors

The editorial board of Molecules (IF: 4.927, ISSN 1420-3049) invites you to submit an article or review to a Special Issue entitled "Discovery of Small Molecules for Cancer Therapy: Current Challenges, Recent Trends, and Future Perspectives". In the search for more efficient therapies devoid of the drawbacks of traditional cytotoxic chemotherapy, targeted therapies have appeared as a promising approach to maximize therapeutic benefits with negligible side effects. Continuous and significant advances in the understanding of the multi-factorial pathogenesis of cancer have empowered a constant discovery of potential molecular targets and the development of novel targeted therapeutics. Small molecules have advantages over macromolecules for the targeted therapy of cancer in terms of pharmacokinetic profiles, costs, patient compliance, and so on. This Special Issue aims to examine current challenges and recent trends and provide future perspectives to pave the way for small molecule anticancer drug discovery. We would like to invite you to submit research articles and reviews relevant to the discovery of small molecules for cancer therapy.

Guest Editors

Prof. Dr. Mehlika Dilek Altıntop

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey

Prof. Dr. Ahmet Özdemir

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey

Deadline for manuscript submissions

closed (30 June 2024)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



mdpi.com/si/159417

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/ molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

